BioCryst Pharmaceuticals, Inc.
BCRX Healthcare Drug Manufacturers Specialty & Generic
BioCryst Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $874.8 million, up 94.1% from fiscal 2024. In the quarter to June 2026, revenue grew 33.6%, EPS grew 1,450.0%, free cash flow grew 153.2% and total debt rose 15.2%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
Follow BCRX
BioCryst Pharmaceuticals, Inc. (BCRX) Dividend Safety Score
BioCryst Pharmaceuticals, Inc.'s Dividend Safety Score for fiscal 2025 cannot be worked out: does not pay a regular dividend.
Dividend Safety Score, annual
Annual newest first
| Period | Dividend Safety Score | Change (points) |
|---|
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Payout of earnings | 0.00% | — | Pass | 25 |
| Payout of free cash flow | 0.00% | — | Pass | 25 |
| Net debt / EBITDA | 0.61 | — | Pass | 16 |
| Years without a dividend cut | 0 | — | Fail | 0 |
| Years of falling or negative earnings over the last 10 fiscal years | 9 | — | Fail | 0 |
| Dividend Safety Score | n/a — does not pay a regular dividend | — | ||
How the stockrow Dividend Safety Score works
Our own composite, out of 100, for the latest fiscal year: up to 25 points for how little of its earnings the dividend takes, 25 for how little of its free cash flow, 20 for net debt against EBITDA, 20 for the years it has paid without a cut and 10 for how steady earnings per share have been over ten years. How we calculate it.
| 80–100 | Well covered |
|---|---|
| 60–79 | Adequately covered |
| 40–59 | Stretched |
| below 40 | Weakly covered |
Not worked out for a company that pays no regular dividend, for banks and REITs, whose payouts and leverage these measures do not describe, or with fewer than five years of earnings.
Dividend Safety Score against peers
| Company | Dividend Safety Score |
|---|---|
| PAHC Phibro Animal Health Corporation compare | 47 |
| PRGO Perrigo Company plc compare | 16 |
| XERS Xeris Biopharma Holdings, Inc. compare | — |
| PBH Prestige Consumer Healthcare Inc. compare | — |
| BCRX BioCryst Pharmaceuticals, Inc. | — |
| ANIP ANI Pharmaceuticals, Inc. compare | — |
| ALVO Alvotech compare | — |
| SUPN Supernus Pharmaceuticals, Inc. compare | — |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | — |
What Dividend Safety Score is
The stockrow Dividend Safety Score rates how well earnings and free cash flow cover the dividend, with leverage, the dividend’s record and stable earnings.
Up to 25 points for the payout of earnings, 25 for the payout of free cash flow, 20 for net debt ÷ EBITDA, 20 for the years without a dividend cut and 10 for stable earnings